{"id":1622,"date":"2026-04-09T13:07:30","date_gmt":"2026-04-09T13:07:30","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-07-30T19:03:42","modified_gmt":"2026-07-30T19:03:42","slug":"kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/","title":{"rendered":"Kainova Therapeutics Expands Phase I \/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe"},"content":{"rendered":"\n<p><strong>Montreal, Canada \u2013 Strasbourg, France \u2013 Boston, United States, April 9, 2026:&nbsp;<\/strong>Kainova Therapeutics ( \u201cthe Company\u201d ), a key player for breakthrough treatments in immuno-oncology and inflammation, today announced dosing of the first patient in the European expansion of its DOMISOL Phase I \/ II clinical trial evaluating DT\u20117012, a proprietary Treg\u2011depleting anti\u2011CCR8 monoclonal antibody, in patients with advanced solid tumors.<\/p>\n\n\n\n<p>This dosing follows the initiation of the DOMISOL&nbsp;<a href=\"https:\/\/www.kainovatx.com\/wp-content\/uploads\/default\/20260202\/kainova-pr-28102025-en.pdf\">Phase I \/ II study in Australia, announced in October 2025<\/a>, marking a significant milestone in the global clinical development of DT\u20117012, Kainova Therapeutics\u2019 lead immuno-oncology program. The European expansion (&nbsp;<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06819735\">NCT06819735<\/a>&nbsp;) includes leading oncology centers in France, led by renowned early-phase clinical investigators, including Dr Lauriane Eberst at H\u00f4pitaux Universitaires de Strasbourg, Professor Antoine Italiano at Institut Gustave Roussy in Paris, and Dr Maxime Brunet at Institut Bergoni\u00e9 Bordeaux.<\/p>\n\n\n\n<p><strong>Professor Antoine Italiano, MD PhD, Head of Precision Medicine at Institut Gustave Roussy and member of Kainova Therapeutics\u2019 Scientific Advisory Board, said:<\/strong>&nbsp;<em>\u201cThis study brings together strong clinical expertise and advanced translational capabilities, creating an important opportunity to explore how targeted Treg depletion may translate into meaningful benefit for patients with advanced solid tumors. DT\u20117012 offers a novel, differentiated approach to precisely address CCR8 biology and reshape the tumor microenvironment.\u201d<\/em><\/p>\n\n\n\n<p><strong>Dr Jean<\/strong><strong>\u2011<\/strong><strong>Marie Cuillerot, Chief Medical Officer of Kainova Therapeutics, commented:<\/strong>&nbsp;<em>\u201cDosing of the first patient in Europe marks an important step in the clinical maturation of our flagship program, DT\u20117012. The DOMISOL study has been designed to generate a comprehensive clinical and biological profile for DT\u20117012 across both monotherapy and combination settings, including paired biopsies to directly assess the intra tumoral Treg depletion. These data will be essential to inform dose selection and support the next phases of development.\u201d<\/em><\/p>\n\n\n\n<p>The Phase I \/ II multicenter, open\u2011label DOMISOL clinical study is evaluating DT\u20117012 as monotherapy in a Phase I dose-escalation, in combination with the immune checkpoint inhibitor pembrolizumab in a Phase Ib dose-escalation in patients with advanced solid tumors, and in selected tumor types in a Phase II component focused on clinical efficacy. The primary objectives include determining the maximum tolerated dose ( MTD ) or maximum administered dose ( MAD ) of DT\u20117012 as monotherapy and assessing the safety and tolerability of DT\u20117012 in combination with pembrolizumab.<\/p>\n\n\n\n<p>The study also includes a translational research program with paired tumor biopsies to evaluate intratumoral Treg depletion induced by DT\u20117012, providing a direct demonstration of DT-7012\u2019s mechanism of action to turn the immunosuppressive tumor microenvironment into an immunocompetent one.<\/p>\n\n\n\n<p><strong>Sean A. MacDonald, Chief Executive Officer of Kainova Therapeutics, added:<\/strong>&nbsp;<em>\u201cAs our flagship program, DT\u20117012 is central to Kainova Therapeutics\u2019 strategy and reflects our commitment to advancing breakthrough GPCR\u2011modulating therapies in immuno\u2011oncology and inflammation. With multiple high\u2011value milestones ahead, 2026 is a pivotal year for Kainova Therapeutics. We are excited to expand the DOMISOL trial into Europe and we look forward to sharing compelling data in the coming quarters.\u201d<\/em><\/p>\n\n\n\n<p><strong>For more information, please contact:<\/strong><br>Optimum Strategic Communications<br>Mary Clark, Zoe Bolt, Elena Bates, Nellie Stephens<br>+44 (0) 203 882 9621<br><a href=\"mailto:kainova@optimumcomms.com\">kainova@optimumcomms.com<\/a><\/p>\n\n\n\n<p>For French media:<br><a href=\"mailto:communication@kainovatx.com\">communication@kainovatx.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.kainovatx.com\/en\/press-releases\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/\">Read the original press release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Montreal, Canada \u2013 Strasbourg, France \u2013 Boston, United States, April 9, 2026:&nbsp;Kainova Therapeutics ( \u201cthe Company\u201d ), a key player for breakthrough treatments in immuno-oncology and inflammation, today announced dosing [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1623,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"company":[79],"class_list":["post-1622","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-portfolio-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kainova Therapeutics Expands Phase I \/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kainova Therapeutics Expands Phase I \/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe | adMare\" \/>\n<meta property=\"og:description\" content=\"Montreal, Canada \u2013 Strasbourg, France \u2013 Boston, United States, April 9, 2026:&nbsp;Kainova Therapeutics ( \u201cthe Company\u201d ), a key player for breakthrough treatments in immuno-oncology and inflammation, today announced dosing [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T13:07:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-30T19:03:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1198\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Kainova Therapeutics Expands Phase I \\\/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe\",\"datePublished\":\"2026-04-09T13:07:30+00:00\",\"dateModified\":\"2026-07-30T19:03:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/\"},\"wordCount\":533,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861.png\",\"articleSection\":[\"Portfolio Companies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/\",\"name\":\"Kainova Therapeutics Expands Phase I \\\/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861.png\",\"datePublished\":\"2026-04-09T13:07:30+00:00\",\"dateModified\":\"2026-07-30T19:03:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861.png\",\"width\":1198,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Kainova Therapeutics Expands Phase I \\\/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kainova Therapeutics Expands Phase I \/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Kainova Therapeutics Expands Phase I \/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe | adMare","og_description":"Montreal, Canada \u2013 Strasbourg, France \u2013 Boston, United States, April 9, 2026:&nbsp;Kainova Therapeutics ( \u201cthe Company\u201d ), a key player for breakthrough treatments in immuno-oncology and inflammation, today announced dosing [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/","og_site_name":"adMare","article_published_time":"2026-04-09T13:07:30+00:00","article_modified_time":"2026-07-30T19:03:42+00:00","og_image":[{"width":1198,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Kainova Therapeutics Expands Phase I \/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe","datePublished":"2026-04-09T13:07:30+00:00","dateModified":"2026-07-30T19:03:42+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/"},"wordCount":533,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png","articleSection":["Portfolio Companies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/","name":"Kainova Therapeutics Expands Phase I \/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png","datePublished":"2026-04-09T13:07:30+00:00","dateModified":"2026-07-30T19:03:42+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png","width":1198,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-expands-phase-i-ii-trial-of-dt-7012-a-treg-depleting-anti-ccr8-antibody-with-first-patient-dosed-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Kainova Therapeutics Expands Phase I \/ II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=1622"}],"version-history":[{"count":2,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1622\/revisions"}],"predecessor-version":[{"id":2494,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1622\/revisions\/2494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/1623"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=1622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=1622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=1622"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=1622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}